<DOC>
	<DOCNO>NCT00033904</DOCNO>
	<brief_summary>Determine whether patient receive adjuvant HSPPC-96 treatment surgically resect , locally advanced renal cell carcinoma improve recurrence-free survival compare subject adjuvant treatment .</brief_summary>
	<brief_title>Survival Study Of OncophageÂ® v . Observation In Patients With Kidney Cancer</brief_title>
	<detailed_description>Primary Objective : - The primary objective study determine whether subject randomize receive adjuvant HSPPC-96 surgical resection locally advance renal cell carcinoma high risk recurrence , improve recurrence-free survival compare subject adjuvant treatment . Secondary Objective : - Determine whether subject randomize receive HSPPC-96 improve survival compare subject adjuvant treatment . - Further characterize safety profile HSPPC-96 .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>PreSurgery Primaryintact resectable renal cell cancer , without know distant metastasis schedule surgery curative intent ; Tumor size great equal 5 cm OR macroscopic node OR renal vein thrombus OR vena cava thrombus radiologic evaluation Performance status ( Zubrod / ECOGWHO scale ) less equal 1 life expectancy great three month , within 2 week surgery . Women childbearing potential must negative urine serum pregnancy test within 2 week surgery . Signed write informed consent . PreSurgery Prior chemo , hormonal , immuno radiotherapy renal cell cancer ; History primary secondary immunodeficiency , patient use immunosuppressive drug , e.g . systemic corticosteroid , cyclosporin A ; Current malignancy sit previous cancer within last 5 year , exception adequately treat conebiopsied situ carcinoma cervix uteri basal squamous cell carcinoma skin ; Embolization renal artery prior nephrectomy ; Known distant metastasis ; Active , uncontrolled infection serious medical illness . Eligibility Assessment : ( 2 week pre 4 week postsurgery ) Prior randomization entry tumor evaluation phase , subject must undergo test confirm free distant metastatic disease , meet criterion . Eligibility Criteria must assess confirm prior randomization : No evidence metastatic residual renal carcinoma document follow : abdominal/pelvis CT scan ; chest CT scan ; brain CT MRI scan . Provide Antigenics great equal 7 gram viable tumor tissue Adequate bone marrow function . Adequate renal hepatic function . Adequate cardiac function . Signed write informed consent . Patients must willing follow course tumor evaluation followup phase . Male female patient child produce potential must agree use adequate contraception treatment/observation phase study . Patients must use investigational drug four week prior start tumor evaluation phase throughout tumor evaluation phase study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Kidney Cancer , renal , immunotherapy , tumor ,</keyword>
</DOC>